skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

15319

Testing whether drugs that weaken norepinephrine signaling prevent or treat various types of cancer



Commentary

(6840) Total Article Views


Authors: Paul J Fitzgerald

Published Date December 2009 Volume 2010:2 Pages 1 - 3
DOI: http://dx.doi.org/10.2147/CLEP.S8903

Paul J Fitzgerald

The Zanvyl Krieger Mind/Brain Institute, Solomon H. Snyder, Department of Neuroscience, Johns Hopkins University, Baltimore, MD, USA

Abstract: Recently, I put forth the hypothesis that the signaling molecule, norepinephrine (NE), is an etiological factor in a number of types of cancer. In this brief commentary, I summarize evidence that NE plays a role in cancer and describe details involved in testing the hypothesis in humans through epidemiological investigation of existing medical records of persons who have taken pharmaceutical drugs that affect NE. If NE plays an etiological role in cancers of a number of organs, then taking a single pharmaceutical drug (such as clonidine, prazosin, or propranolol) that weakens NE signaling systemically, may simultaneously prevent or treat many different types of cancer, and this may represent a breakthrough in pharmaceutical prevention and possibly treatment of cancer.

Keywords: norepinephrine, acetylcholine, cancer, clonidine, prazosin, propranolol




Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter

 

Other articles by Dr P J Fitzgerald


Readers of this article also read: